Home/Filings/4/0001214659-18-006692
4//SEC Filing

Wasoff Evan L 4

Accession 0001214659-18-006692

CIK 0001625288other

Filed

Oct 29, 8:00 PM ET

Accepted

Oct 30, 1:59 PM ET

Size

7.4 KB

Accession

0001214659-18-006692

Insider Transaction Report

Form 4
Period: 2018-10-26
Wasoff Evan L
Chief Financial Officer
Transactions
  • Award

    Stock option - right to buy

    2018-10-26+200,000200,000 total
    Exercise: $0.66From: 2018-10-26Exp: 2025-10-26Common Stock (200,000 underlying)
Holdings
  • Common Stock

    1,000,000
  • Stock option - right to buy

    Exercise: $0.54From: 2018-07-25Exp: 2025-07-25Common Stock (420,000 underlying)
    420,000
Footnotes (2)
  • [F1]Granted under the Company's 2018 Equity Incentive Plan.
  • [F2]35,000 options vested immediately, with the remainder vesting monthly over the next 11 months beginning August 1, 2018.

Issuer

NEXIEN BIOPHARMA, INC.

CIK 0001625288

Entity typeother

Related Parties

1
  • filerCIK 0001719738

Filing Metadata

Form type
4
Filed
Oct 29, 8:00 PM ET
Accepted
Oct 30, 1:59 PM ET
Size
7.4 KB